

Stephen T Abedon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1988838/publications.pdf>

Version: 2024-02-01

91
papers

8,059
citations

66234

42
h-index

88477

70
g-index

114
all docs

114
docs citations

114
times ranked

5363
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Phage treatment of human infections. <i>Bacteriophage</i> , 2011, 1, 66-85. | 1.9 | 734 |
| 2 | Phage cocktails and the future of phage therapy. <i>Future Microbiology</i> , 2013, 8, 769-783. | 1.0 | 692 |
| 3 | Pros and cons of phage therapy. <i>Bacteriophage</i> , 2011, 1, 111-114. | 1.9 | 691 |
| 4 | Bacteriophage Host Range and Bacterial Resistance. <i>Advances in Applied Microbiology</i> , 2010, 70, 217-248. | 1.3 | 572 |
| 5 | Phage Therapy in Clinical Practice: Treatment of Human Infections. <i>Current Pharmaceutical Biotechnology</i> , 2010, 11, 69-86. | 0.9 | 550 |
| 6 | Lysogeny in nature: mechanisms, impact and ecology of temperate phages. <i>ISME Journal</i> , 2017, 11, 1511-1520. | 4.4 | 510 |
| 7 | Lysis from without. <i>Bacteriophage</i> , 2011, 1, 46-49. | 1.9 | 293 |
| 8 | Phage Therapy Pharmacology. <i>Current Pharmaceutical Biotechnology</i> , 2010, 11, 28-47. | 0.9 | 214 |
| 9 | Bacteriophage Latent-Period Evolution as a Response to Resource Availability. <i>Applied and Environmental Microbiology</i> , 2001, 67, 4233-4241. | 1.4 | 211 |
| 10 | Editorial: Phage Therapy: Past, Present and Future. <i>Frontiers in Microbiology</i> , 2017, 8, 981. | 1.5 | 163 |
| 11 | Bacteriophages and their Enzymes in Biofilm Control. <i>Current Pharmaceutical Design</i> , 2014, 21, 85-99. | 0.9 | 160 |
| 12 | Phage Therapy Pharmacology. <i>Advances in Applied Microbiology</i> , 2012, 78, 1-23. | 1.3 | 156 |
| 13 | Diversity of phage infection types and associated terminology: the problem with "Lytic or lysogenic". <i>FEMS Microbiology Letters</i> , 2016, 363, fnw047. | 0.7 | 156 |
| 14 | Experimental Examination of Bacteriophage Latent-Period Evolution as a Response to Bacterial Availability. <i>Applied and Environmental Microbiology</i> , 2003, 69, 7499-7506. | 1.4 | 136 |
| 15 | Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies. <i>Microbiology and Molecular Biology Reviews</i> , 2019, 83, . | 2.9 | 116 |
| 16 | Re-establishing a place for phage therapy in western medicine. <i>Future Microbiology</i> , 2015, 10, 685-688. | 1.0 | 111 |
| 17 | Kinetics of Phage-Mediated Biocontrol of Bacteria. <i>Foodborne Pathogens and Disease</i> , 2009, 6, 807-815. | 0.8 | 107 |
| 18 | Phage therapy dosing: The problem(s) with multiplicity of infection (MOI). <i>Bacteriophage</i> , 2016, 6, e1220348. | 1.9 | 107 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Chapter 1 Phage Evolution and Ecology. <i>Advances in Applied Microbiology</i> , 2009, 67, 1-45. | 1.3 | 103 |
| 20 | Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?. <i>Antibiotics</i> , 2019, 8, 182. | 1.5 | 94 |
| 21 | Bacteriophage Plaques: Theory and Analysis. <i>Methods in Molecular Biology</i> , 2009, 501, 161-174. | 0.4 | 92 |
| 22 | The Roles of the Bacteriophage T4 r Genes in Lysis Inhibition and Fine-Structure Genetics: A New Perspective. <i>Genetics</i> , 1998, 148, 1539-1550. | 1.2 | 85 |
| 23 | Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria. <i>Pharmaceuticals</i> , 2015, 8, 559-589. | 1.7 | 81 |
| 24 | Phage therapy of pulmonary infections. <i>Bacteriophage</i> , 2015, 5, e1020260. | 1.9 | 79 |
| 25 | Bacterial "immunity" against bacteriophages. <i>Bacteriophage</i> , 2012, 2, 50-54. | 1.9 | 78 |
| 26 | Bacteriophage prehistory. <i>Bacteriophage</i> , 2011, 1, 174-178. | 1.9 | 77 |
| 27 | Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?. <i>FEMS Microbiology Letters</i> , 2016, 363, fmv246. | 0.7 | 76 |
| 28 | Phage "delay" towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. <i>AIMS Microbiology</i> , 2017, 3, 186-226. | 1.0 | 74 |
| 29 | Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. <i>Pharmaceuticals</i> , 2021, 14, 1019. | 1.7 | 72 |
| 30 | Information Phage Therapy Research Should Report. <i>Pharmaceuticals</i> , 2017, 10, 43. | 1.7 | 70 |
| 31 | Spatial Vulnerability: Bacterial Arrangements, Microcolonies, and Biofilms as Responses to Low Rather than High Phage Densities. <i>Viruses</i> , 2012, 4, 663-687. | 1.5 | 68 |
| 32 | Selection for lysis inhibition in bacteriophage. <i>Journal of Theoretical Biology</i> , 1990, 146, 501-511. | 0.8 | 67 |
| 33 | Optimizing bacteriophage plaque fecundity. <i>Journal of Theoretical Biology</i> , 2007, 249, 582-592. | 0.8 | 62 |
| 34 | Coming-of-Age Characterization of Soil Viruses: A User's Guide to Virus Isolation, Detection within Metagenomes, and Viromics. <i>Soil Systems</i> , 2020, 4, 23. | 1.0 | 61 |
| 35 | Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. <i>Pharmaceuticals</i> , 2015, 8, 525-558. | 1.7 | 60 |
| 36 | Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. <i>Advanced Drug Delivery Reviews</i> , 2019, 145, 18-39. | 6.6 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Bacteriophage secondary infection. <i>Virologica Sinica</i> , 2015, 30, 3-10. | 1.2 | 53 |
| 38 | Look Who's Talking: T-Even Phage Lysis Inhibition, the Granddaddy of Virus-Virus Intercellular Communication Research. <i>Viruses</i> , 2019, 11, 951. | 1.5 | 52 |
| 39 | Why Bacteriophage Encode Exotoxins and other Virulence Factors. <i>Evolutionary Bioinformatics</i> , 2005, 1, 117693430500100. | 0.6 | 46 |
| 40 | Bacteriophage evolution given spatial constraint. <i>Journal of Theoretical Biology</i> , 2007, 248, 111-119. | 0.8 | 46 |
| 41 | Bacteriophage T4 resistance to lysis-inhibition collapse. <i>Genetical Research</i> , 1999, 74, 1-11. | 0.3 | 45 |
| 42 | The Murky Origin of Snow White and Her T-Even Dwarfs. <i>Genetics</i> , 2000, 155, 481-486. | 1.2 | 45 |
| 43 | Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. <i>Antibiotics</i> , 2021, 10, 1497. | 1.5 | 44 |
| 44 | Phage Therapy: Eco-Physiological Pharmacology. <i>Scientifica</i> , 2014, 2014, 1-29. | 0.6 | 40 |
| 45 | Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent. <i>Microbiology Spectrum</i> , 2017, 5, . | 1.2 | 40 |
| 46 | Phage Therapy: The Pharmacology of Antibacterial Viruses. <i>Current Issues in Molecular Biology</i> , 2021, 40, 81-164. | 1.0 | 40 |
| 47 | Why bacteriophage encode exotoxins and other virulence factors. <i>Evolutionary Bioinformatics</i> , 2007, 1, 97-110. | 0.6 | 40 |
| 48 | Phage Therapy: Various Perspectives on How to Improve the Art. <i>Methods in Molecular Biology</i> , 2018, 1734, 113-127. | 0.4 | 35 |
| 49 | Smaller Fleas: Viruses of Microorganisms. <i>Scientifica</i> , 2012, 2012, 1-23. | 0.6 | 32 |
| 50 | Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?. <i>Pharmaceuticals</i> , 2021, 14, 1157. | 1.7 | 32 |
| 51 | Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes. <i>AIMS Microbiology</i> , 2017, 3, 649-688. | 1.0 | 31 |
| 52 | Commentary: Communication between Viruses Guides Lysis/Lysogeny Decisions. <i>Frontiers in Microbiology</i> , 2017, 8, 983. | 1.5 | 30 |
| 53 | Basic Phage Mathematics. <i>Methods in Molecular Biology</i> , 2018, 1681, 3-30. | 0.4 | 28 |
| 54 | Thinking about microcolonies as phage targets. <i>Bacteriophage</i> , 2012, 2, 200-204. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Envisaging bacteria as phage targets. <i>Bacteriophage</i> , 2011, 1, 228-230. | 1.9 | 20 |
| 56 | Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model. <i>Frontiers in Microbiology</i> , 2016, 7, 1251. | 1.5 | 19 |
| 57 | Improving Phage-Biofilm In Vitro Experimentation. <i>Viruses</i> , 2021, 13, 1175. | 1.5 | 19 |
| 58 | Archaeal Viruses, Not Archaeal Phages: An Archaeological Dig. <i>Archaea</i> , 2013, 2013, 1-10. | 2.3 | 16 |
| 59 | Phages, ecology, evolution. , 2008, , 1-28. | | 15 |
| 60 | Bacteriophage-Mediated Biocontrol of Wound Infections, and Ecological Exploitation of Biofilms by Phages. <i>Recent Clinical Techniques, Results, and Research in Wounds</i> , 2018, , 121-158. | 0.1 | 15 |
| 61 | Commentary: A Host-Produced Quorum-Sensing Autoinducer Controls a Phage Lysis-Lysogeny Decision. <i>Frontiers in Microbiology</i> , 2019, 10, 1171. | 1.5 | 15 |
| 62 | Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism of <i>Pseudomonas aeruginosa</i> Phages. <i>Pharmaceuticals</i> , 2021, 14, 1162. | 1.7 | 15 |
| 63 | Phage population growth: constraints, games, adaptation. , 0, , 64-93. | | 14 |
| 64 | Communication Among Phages, Bacteria, and Soil Environments. <i>Soil Biology</i> , 2011, , 37-65. | 0.6 | 14 |
| 65 | Fighting Fire with Fire: Phage Potential for the Treatment of <i>E. coli</i> O157 Infection. <i>Antibiotics</i> , 2018, 7, 101. | 1.5 | 12 |
| 66 | Modeling bacteriophage population growth. , 0, , 389-414. | | 11 |
| 67 | Facilitation of CRISPR adaptation. <i>Bacteriophage</i> , 2011, 1, 179-181. | 1.9 | 11 |
| 68 | Phages, bacteria, and food. , 2008, , 302-331. | | 10 |
| 69 | Modeling phage plaque growth. , 0, , 415-438. | | 9 |
| 70 | Bacteriophage Ecology. , 2021, , 253-294. | | 9 |
| 71 | Detection of Bacteriophages: Phage Plaques. , 2021, , 507-538. | | 9 |
| 72 | Phage Ecology and Bacterial Pathogenesis. , 0, , 66-91. | | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Phage ecology of bacterial pathogenesis. , 2008, , 353-386. | | 8 |
| 74 | Impact of spatial structure on phage population growth. , 2008, , 94-113. | | 7 |
| 75 | Phage-Phage, Phage-Bacteria, and Phage-Environment Communication. , 2020, , 23-70. | | 7 |
| 76 | Detection of Bacteriophages: Phage Plaques. , 2018, , 1-32. | | 7 |
| 77 | Virus ecology and disturbances: impact of environmental disruption on the viruses of microorganisms. <i>Frontiers in Microbiology</i> , 2014, 5, 700. | 1.5 | 6 |
| 78 | Virus-Like Particle: Evolving Meanings in Different Disciplines. <i>Phage</i> , 2021, 2, 11-15. | 0.8 | 6 |
| 79 | Bacteriophages as Drivers of Evolution. , 2022, , . | | 6 |
| 80 | Further Considerations on How to Improve Phage Therapy Experimentation, Practice, and Reporting: Pharmacodynamics Perspectives. <i>Phage</i> , 2022, 3, 98-111. | 0.8 | 6 |
| 81 | Pathways to Phage Therapy Enlightenment, or Why I Have Become a Scientific Curmudgeon. <i>Phage</i> , 2022, 3, 95-97. | 0.8 | 5 |
| 82 | Bacteriophage Ecology. , 2020, , 1-42. | | 4 |
| 83 | Are archaeons incapable of being parasites or have we simply failed to notice?. <i>BioEssays</i> , 2013, 35, 501-501. | 1.2 | 3 |
| 84 | Bacteriophage Pharmacology and Immunology. , 2021, , 295-339. | | 3 |
| 85 | Bacteriophage Clinical Use as Antibacterial “Drugs” Utility and Precedent. , 0, , 417-451. | | 2 |
| 86 | An online phage therapy bibliography: separating under-indexed wheat from overly indexed chaff. <i>AIMS Microbiology</i> , 2017, 3, 525-528. | 1.0 | 2 |
| 87 | Bacteriophage Pharmacology and Immunology. , 2018, , 1-45. | | 2 |
| 88 | Salutary Contributions of Viruses to Medicine and Public Health. , 2012, , 389-405. | | 1 |
| 89 | Prophages Preventing Phage Superinfection. , 2022, , 179-191. | | 1 |
| 90 | Transduction of Large Amounts of DNA. , 2022, , 137-150. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------|----|-----------|
| 91 | Phage Morons. , 2022, , 153-164. | | 1 |